About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

NCT02754882·105 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Samsung Bioepis Co., Ltd.

Standard efficacy parameters, safety profiles, pharmacokinetics and immunogenicity will be compared between SB8 and bevacizumab.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Aged ≥ 18 years
2. ECOG performance status of 0-1
3. Histologically-confirmed metastatic or recurrent non-squamous non-small cell lung cancer
4. At least one measurable lesion according to RECIST v1.1.
5. Able to receive bevacizumab, carboplatin and paclitaxel based on adequate laboratory and clinical parameters

You may not be if

1. Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma
2. Sensitizing EGFR mutations or ALK rearrangements
3. Increased risk of bleeding determined by investigator based on radiographic / clinical findings
4. History of systemic chemotherapy administered in the first-line setting for metastatic or recurrent disease of NSCLC.

The record

StatusCompleted

PhasePhase 3

Taking part763

StartedJul 2016

UpdatedDec 16, 2024

Conditions

Lung Cancer Non-small Cell Lung Cancer

Where105

Brest Regional Oncology Dispensary
Brest, Belarus
Grodno Regional Clinical Hospital
Grodno, Belarus
N. N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology
Lesnoy, Belarus